Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1993 Dec;110(4):1600–1606. doi: 10.1111/j.1476-5381.1993.tb14007.x

ZD1542, a potent thromboxane A2 synthase inhibitor and receptor antagonist in vitro.

R P Brownlie 1, N J Brownrigg 1, H M Butcher 1, R Garcia 1, R Jessup 1, V J Lee 1, S Tunstall 1, M G Wayne 1
PMCID: PMC2175849  PMID: 8306107

Abstract

1. The thromboxane A2 synthase (TXS) inhibitory activity and the thromboxane A2 (TP)-receptor blocking action of ZD1542 (4(Z)-6-[2S,4S,5R)-2-[1-methyl-1-(2-nitro-4-tolyloxy)ethyl]-4-(3- pyridyl)-1,3-dioxan-5-yl]hex-4-enoic acid) has been evaluated in vitro on platelets and whole blood from a range of species including man. Antagonist activity has also been investigated in vascular and pulmonary smooth muscle preparations in vitro. 2. ZD1542 caused concentration-dependent inhibition of human platelet microsomal thromboxane B2 (TXB2) production in vitro (IC50 = 0.016 microM); this inhibition was associated with an increase in prostaglandin E2 (PGE2) and PGF2 alpha formation. 3. ZD1542 also inhibited collagen-stimulated TXS in human, rat and dog whole blood giving IC50 values of 0.018, 0.009 and 0.049 microM respectively. The drug did not modify platelet cyclo-oxygenase activity as inhibition of TXB2 formation was associated with a concomitant increase in the levels of PGD2, PGE2 and PGF2 alpha. ZD1542 had little if any effect against cultured human umbilical vein endothelial cell (HUVEC) cyclo-oxygenase (IC50 > 100 microM) and prostacyclin (PGI2) synthase (IC50 = 18.0 +/- 8.6 microM). 4. ZD1542 caused concentration-dependent inhibition of U46619-induced aggregation responses of human, rat and dog platelets yielding apparent pA2 values of 8.3, 8.5 and 9.1 respectively. The drug was selective as, at concentrations up to 100 microM, it did not modify 5-hydroxytryptamine (5-HT) or the primary phases of adenosine diphosphate (ADP) and adrenaline-induced aggregation. Furthermore, ZD1542 (100 microM) modified only weakly the platelet effects of PGD2, PGE1 and PGI2.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
1600

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ARUNLAKSHANA O., SCHILD H. O. Some quantitative uses of drug antagonists. Br J Pharmacol Chemother. 1959 Mar;14(1):48–58. doi: 10.1111/j.1476-5381.1959.tb00928.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Ambler J., Butler K. D., Ku E. C., Maguire E. D., Smith J. R., Wallis R. B. CGS 12970: a novel, long acting thromboxane synthetase inhibitor. Br J Pharmacol. 1985 Oct;86(2):497–504. doi: 10.1111/j.1476-5381.1985.tb08920.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bailey I. A., Carey F., Haworth D., Smith H. J. Effects of vascular trauma and transient myocardial ischaemia on coronary venous prostaglandin levels in the dog. Cardiovasc Res. 1983 Mar;17(3):127–131. doi: 10.1093/cvr/17.3.127. [DOI] [PubMed] [Google Scholar]
  4. Bertele V., De Gaetano G. Potentiation by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclin. Eur J Pharmacol. 1982 Dec 3;85(3-4):331–333. doi: 10.1016/0014-2999(82)90220-5. [DOI] [PubMed] [Google Scholar]
  5. Chiabrando C., Rivoltella L., Martelli L., Valzacchi S., Fanelli R. Urinary excretion of thromboxane and prostacyclin metabolites during chronic low-dose aspirin: evidence for an extrarenal origin of urinary thromboxane B2 and 6-keto-prostaglandin F1 alpha in healthy subjects. Biochim Biophys Acta. 1992 Feb 3;1133(3):247–254. doi: 10.1016/0167-4889(92)90044-c. [DOI] [PubMed] [Google Scholar]
  6. Cross P. E., Dickinson R. P., Parry M. J., Randall M. J. Selective thromboxane synthetase inhibitors. 1. 1-[(Aryloxy)alkyl]-1H-imidazoles. J Med Chem. 1985 Oct;28(10):1427–1432. doi: 10.1021/jm00148a009. [DOI] [PubMed] [Google Scholar]
  7. De Clerck F., Beetens J., de Chaffoy de Courcelles D., Freyne E., Janssen P. A. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--I. Biochemical profile in vitro. Thromb Haemost. 1989 Feb 28;61(1):35–42. [PubMed] [Google Scholar]
  8. Forder R. A., Carey F. Measurement of human venous plasma prostacyclin and metabolites by radioimmunoassay: a reappraisal. Prostaglandins Leukot Med. 1983 Nov;12(3):323–346. doi: 10.1016/0262-1746(83)90011-2. [DOI] [PubMed] [Google Scholar]
  9. Garcia J. G., Azghani A., Callahan K. S., Johnson A. R. Effect of platelet activating factor on leukocyte-endothelial cell interactions. Thromb Res. 1988 Jul 1;51(1):83–96. doi: 10.1016/0049-3848(88)90285-x. [DOI] [PubMed] [Google Scholar]
  10. Gresele P., Arnout J., Deckmyn H., Huybrechts E., Pieters G., Vermylen J. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism. J Clin Invest. 1987 Nov;80(5):1435–1445. doi: 10.1172/JCI113223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Gresele P., Corona C., Alberti P., Nenci G. G. Picotamide protects mice from death in a pulmonary embolism model by a mechanism independent from thromboxane suppression. Thromb Haemost. 1990 Aug 13;64(1):80–86. [PubMed] [Google Scholar]
  12. Gresele P., Deckmyn H., Nenci G. G., Vermylen J. Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic disorders. Trends Pharmacol Sci. 1991 Apr;12(4):158–163. doi: 10.1016/0165-6147(91)90533-x. [DOI] [PubMed] [Google Scholar]
  13. Hamberg M., Svensson J., Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A. 1975 Aug;72(8):2994–2998. doi: 10.1073/pnas.72.8.2994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Haworth D., Carey F. Thromboxane synthase inhibition: implications for prostaglandin endoperoxide metabolism. I. Characterisation of an acute intravenous challenge model to measure prostaglandin endoperoxide metabolism. Prostaglandins. 1986 Jan;31(1):33–45. doi: 10.1016/0090-6980(86)90223-6. [DOI] [PubMed] [Google Scholar]
  15. Hoet B., Falcon C., De Reys S., Arnout J., Deckmyn H., Vermylen J. R68070, a combined thromboxane/endoperoxide receptor antagonist and thromboxane synthase inhibitor, inhibits human platelet activation in vitro and in vivo: a comparison with aspirin. Blood. 1990 Feb 1;75(3):646–653. [PubMed] [Google Scholar]
  16. Jessup C. L., Jessup R., Wayne M. Pharmacological actions of ICI 180080, a novel thromboxane receptor antagonist. J Pharm Pharmacol. 1986 Oct;38(10):754–757. doi: 10.1111/j.2042-7158.1986.tb04484.x. [DOI] [PubMed] [Google Scholar]
  17. Kennedy I., Coleman R. A., Humphrey P. P., Levy G. P., Lumley P. Studies on the characterisation of prostanoid receptors: a proposed classification. Prostaglandins. 1982 Nov;24(5):667–689. doi: 10.1016/0090-6980(82)90036-3. [DOI] [PubMed] [Google Scholar]
  18. Kyrle P. A., Eichler H. G., Jäger U., Lechner K. Inhibition of prostacyclin and thromboxane A2 generation by low-dose aspirin at the site of plug formation in man in vivo. Circulation. 1987 May;75(5):1025–1029. doi: 10.1161/01.cir.75.5.1025. [DOI] [PubMed] [Google Scholar]
  19. Lumley P., Keery R. J., Wharton K. A., White B. P., Watts I. S. Maximal blockade of TxA2 without compromised PGI2 formation; a superior profile of the TxA2 receptor blocking drug GR32191 over aspirin. Adv Prostaglandin Thromboxane Leukot Res. 1991;21B:603–606. [PubMed] [Google Scholar]
  20. Patrono C. Aspirin and human platelets: from clinical trials to acetylation of cyclooxygenase and back. Trends Pharmacol Sci. 1989 Nov;10(11):453–458. doi: 10.1016/S0165-6147(89)80010-0. [DOI] [PubMed] [Google Scholar]
  21. Reilly I. A., Doran J. B., Smith B., FitzGerald G. A. Increased thromboxane biosynthesis in a human preparation of platelet activation: biochemical and functional consequences of selective inhibition of thromboxane synthase. Circulation. 1986 Jun;73(6):1300–1309. doi: 10.1161/01.cir.73.6.1300. [DOI] [PubMed] [Google Scholar]
  22. Reilly I. A., FitzGerald G. A. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood. 1987 Jan;69(1):180–186. [PubMed] [Google Scholar]
  23. Terashita Z., Imura Y., Tanabe M., Kawazoe K., Nishikawa K., Kato K., Terao S. CV-4151--a potent, selective thromboxane A2 synthetase inhibitor. Thromb Res. 1986 Jan 15;41(2):223–237. doi: 10.1016/0049-3848(86)90231-8. [DOI] [PubMed] [Google Scholar]
  24. Ullrich V., Haurand M. Thromboxane synthase as a cytochrome P450 enzyme. Adv Prostaglandin Thromboxane Leukot Res. 1983;11:105–110. [PubMed] [Google Scholar]
  25. Uotila P., Matintalo M. Inhibition of thromboxane synthetase by OKY-1581 stimulates the formation of PGE2, PGF2 alpha, PGD2 and 6-keto-PGF1 alpha in human platelets. Prostaglandins Leukot Med. 1984 Apr;14(1):41–46. doi: 10.1016/0262-1746(84)90022-2. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES